Elevated markers of thrombo-inflammatory activation predict outcome in patients with cardiovascular comorbidities and CO
- PDF / 1,213,021 Bytes
- 12 Pages / 595.276 x 790.866 pts Page_size
- 67 Downloads / 199 Views
ORIGINAL PAPER
Elevated markers of thrombo‑inflammatory activation predict outcome in patients with cardiovascular comorbidities and COVID‑19 disease: insights from the LEOSS registry Sebastian Cremer1,2,3 · Carolin Jakob4 · Alexander Berkowitsch1 · Stefan Borgmann5 · Lisa Pilgram12 · Lukas Tometten6 · Annika Classen4 · Kai Wille7 · Simon Weidlich8 · Beate Gruener9 · Stefanie Dimmeler2,3,10 · Steffen Massberg11 · Siegbert Rieg13 · Andreas M. Zeiher1,2,3 on behalf of the LEOSS study group Received: 12 August 2020 / Accepted: 21 October 2020 © The Author(s) 2020
Abstract Aims SARS-CoV-2 infection is associated with adverse outcomes in patients with cardiovascular disease. Here, we analyzed whether specific biomarkers predict the clinical course of COVID-19 in patients with cardiovascular comorbidities. Methods and results We enrolled 2147 patients with SARS-CoV-2 infection which were included in the Lean European Open Survey on SARS-CoV‑2 (LEOSS)-registry from March to June 2020. Clinical data and laboratory values were collected and compared between patients with and without cardiovascular comorbidities in different clinical stages of the disease. Predictors for mortality were calculated using multivariate regression analysis. We show that patients with cardiovascular comorbidities display significantly higher markers of myocardial injury and thrombo-inflammatory activation already in the uncomplicated phase of COVID-19. In multivariate analysis, elevated levels of troponin [OR 1.54; (95% CI 1.22–1.96), p 5 LN U 2x
al
LN
U
m or
CRP
p=0.049 n=85/47
p= 0.624 n=50/19
40
0
>
>
N
C
80 % of Patients
50
0
Fibrinogen
p=0.112 n=65/33
% of Patients
25
D-Dimers
50
% of Patients
% of Patients
50
B
Creatinine
p=0.257 n=57/32
% of Patients
A
0 -1
dl g/ 15 dl > g/ 9 4. dl g/ 9 1. -1 l
12
10
dl
/d
g/
dl
9g
9.
8-
9
0 l
0
00
/
00
.0
l
0-
20
45
00
0-
0.
g/
7.
12
50
9 99 -8 l 00 9/ 50 99 -4 l 00 / 20 999 1 l 09 50 49 l /
00
0-
30
3 99 -2 l 00 / 15 499 1 l 080 99/ 7 0l
50
9 49 l /
00
0-
30
5
2x
60
30
0
Leukocytes
p=0.665 n=140/49
30
Lymphocytes p=0.006 n=282/149
>
al
30
0
25
LN U
m
LN U
IL-6
p=0.63 n=149/64
15
50
>
or N
x
LN U
Ferritin
15
D
0
>5
2x
LN U
al
30
>
>
m
LN U
LN U
LN U
0x
0x
x
LN U
al
CRP
p=0.254 n=335/178
p= 0.72 n=86/41
40
0 or N
>2
>1
2x
LN U
>5
>
>
m
or N
C
80 % of Patients
50
0
Fibrinogen
p=0.001 n=205/86
% of Patients
50
D-Dimers
50
% of Patients
% of Patients
100
B
Creatinine
p< 0.001 n=184/84
% of Patients
A
50
40
0
0 -1
dl g/ 15 dl > g/ 9 4. dl g/ 9 1. -1 l
12
10
dl
/d
g/
dl
9g
9.
8-
9
0 l
0
00
/
00
.0
l
0-
20
45
00
0-
0.
g/
7.
12
50
9 99 -8 l 00 9/ 50 99 -4 l 00 / 20 999 1 l 09 50 49 l /
00
0-
30
3 99 -2 l 00 / 15 499 1 l 080 99/ 7 0l 50 9 49 l /
00
0-
2 199 l 0- 9/ 00 99 16 15 l 0/ 00 99 12 119 l 9 99 00
80
l
/m
pg
/m
pg
l
l
/m
% of Patients
>
LN U
9/
9
pg
-7
99
0
99
00
1
0-
50 l
l
/m
pg
l
l
ng
Data Loading...
